Table 1.
Comparison of patients’ characteristics between homo-HER2 and hetero-HER2 positive groups in this study
| Characteristics | Hetero-HER2 n = 53 (%) | Homo-HER2 n = 34 (%) | p value |
|---|---|---|---|
| Age | 68 | 62.5 | 0.029 |
| ≥ 67 | 32 (60.4) | 12 (35.3) | |
| < 66 | 21 (39.6) | 22 (64.7) | |
| Sex | 0.357 | ||
| Male | 37 (69.8) | 20 (58.8) | |
| Female | 16 (30.2) | 14 (41.2) | |
| ECOG PS | 0.481 | ||
| 0 | 34(64.2) | 25 (73.5) | |
| 1 | 19 (35.8) | 9 (26.5) | |
| Primary tumor site | 0.335 | ||
| EGJ | 13 (24.5) | 12 (35.3) | |
| Stomach | 40 (75.5) | 22 (64.7) | |
| Histological type | 0.362 | ||
| Differentiated type | 31 (58.5) | 24 (70.6) | |
| Undifferentiated type | 22 (41.5) | 10 (29.4) | |
| Visceral metastasis | 1.000 | ||
| Yes | 28 (52.8) | 18 (52.9) | |
| No | 25 (47.2) | 16 (47.1) | |
| Previous gastrectomy | 1.000 | ||
| Yes | 17 (32.1) | 11 (32.4) | |
| No | 36 (67.9) | 23 (67.6) | |
| Platinum-based | 0.039 | ||
| Yes | 46 (86.8) | 34 (100) | |
| No | 7 (13.2) | 0 (0.0) | |
| Conversion surgery | 0.304 | ||
| Yes | 4 (7.5) | 5 (14.7) | |
| No | 49 (92.5) | 29 (85.3) | |
| Second line chemotherapy | 1.000 | ||
| Yes | 40 (75.5) | 25 (73.5) | |
| No | 13 (24.5) | 9 (26.5) | |
| Beyond HER2 targeted therapy | 0.772 | ||
| Yes | 8 (15.1) | 6 (17.6) | |
| No | 45 (84.9) | 28 (82.4) | |
| HER2 status | 0.011 | ||
| IHC 3+ | 44 (83.0) | 34 (100) | |
| IHC 2+/FISH positive | 9 (17.0) | 0 (0.0) | |
| CEA (ng/ml) | 0.498 | ||
| ≥ 5.0 | 31 (58.5) | 23 (67.6) | |
| < 5.0 | 22 (41.5) | 11 (32.4) | |
| CA 19-9 (U/ml) | 0.657 | ||
| ≥ 37.0 | 29 (54.7) | 21 (61.8) | |
| < 37.0 | 24 (45.3) | 13 (38.2) |
Hetero-HER2 Heterogeneously HER2 positive, Homo-HER2 homogeneously HER2 positive, EGJ esophagogastric junction, ECOG PS Eastern Cooperative Oncology Group Performance Status, FISH fluorescence in-situ hybridisation, IHC immunohistochemistry